442 related articles for article (PubMed ID: 26660520)
1. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
[TBL] [Abstract][Full Text] [Related]
3. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
Kato Y; Egusa C; Maeda T; Tsuboi R
J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
[TBL] [Abstract][Full Text] [Related]
5. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
6. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
7. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
Kalac M; Scotto L; Marchi E; Amengual J; Seshan VE; Bhagat G; Ulahannan N; Leshchenko VV; Temkin AM; Parekh S; Tycko B; O'Connor OA
Blood; 2011 Nov; 118(20):5506-16. PubMed ID: 21772049
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
9. Pax5 Re-expression in H460 Cells Treated with the Combination of Demethylating Agent and Histone Deacetylase Inhibitor is Associated with the Enhancement of P53 Binding to Pax5 Promoter Region.
Liang Y; Zeng J; Jelicks L; Ma S; Liu J; Mei J; Perez-Soler R; Zou Y
Curr Cancer Drug Targets; 2017; 17(2):169-176. PubMed ID: 27029827
[TBL] [Abstract][Full Text] [Related]
10. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
Chan DW; Lee JM; Chan PC; Ng IO
Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
van Doorn R; Zoutman WH; Dijkman R; de Menezes RX; Commandeur S; Mulder AA; van der Velden PA; Vermeer MH; Willemze R; Yan PS; Huang TH; Tensen CP
J Clin Oncol; 2005 Jun; 23(17):3886-96. PubMed ID: 15897551
[TBL] [Abstract][Full Text] [Related]
12. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Cooper SJ; von Roemeling CA; Kang KH; Marlow LA; Grebe SK; Menefee ME; Tun HW; Colon-Otero G; Perez EA; Copland JA
Mol Cancer Ther; 2012 Oct; 11(10):2105-15. PubMed ID: 22826467
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Jain N; Odenike O
Expert Opin Pharmacother; 2010 Dec; 11(18):3073-84. PubMed ID: 21080855
[TBL] [Abstract][Full Text] [Related]
14. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Magdinier F; Wolffe AP
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
16. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
17. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
18. Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer.
Obata T; Toyota M; Satoh A; Sasaki Y; Ogi K; Akino K; Suzuki H; Murai M; Kikuchi T; Mita H; Itoh F; Issa JP; Tokino T; Imai K
Clin Cancer Res; 2003 Dec; 9(17):6410-8. PubMed ID: 14695142
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
[TBL] [Abstract][Full Text] [Related]
20. Antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells.
Shaker S; Bernstein M; Momparler RL
Oncol Rep; 2004 Jun; 11(6):1253-6. PubMed ID: 15138563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]